Ashley has reported on health care market issues with Citleline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).
Latest from Ashley Yeo
The long-awaited post market surveillance regulation for medical devices on the Great Britain market will come into force on 16 June.
The UK market has become tougher for smaller innovators, says Andy Mears, CEO of Deltex Medical, which plans to launch a new iteration of its minimally invasive ultrasound-based technology, the oesophageal Doppler monitor. He explained how market access challenges have steepened.
The electronic patient record, a key piece of Germany’s new “DigiG” digital health law, was rolled out on 15 January, presaging more efficient delivery of targeted patient care and new opportunities for medical research informed by data.
Greater reliance on point-of-care testing ticks the patient-centricity box of UK’s proposed elective care reform. But quality oversight from pathology professionals is vital to ensure that the safety and reliability boxes are also ticked, says the Institute of Biomedical Science.
Royal Philips is at the forefront of the driving environmental sustainability along the Scope 1-2-3 chain. The company hosted a round table in Amsterdam to hear experiences from providers.
ZS principal Brian Chapman tells In Vivo what is troubling the global medtech industry at the turn of 2025, and takes the opportunity to chide the EU for its persistent fixation on taking on the “problem that did not need to be solved.”